{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T23:43:24Z","timestamp":1692747804962},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Charit\u00e9"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Medizinische Leitlinien sind systematisch entwickelte Entscheidungshilfen f\u00fcr die angemessene Vorgehensweise bei speziellen gesundheitlichen Problemen. Dermatologische Leitlinien in Deutschland werden f\u00fchrend von der Deutschen Dermatologischen Gesellschaft in Kooperation mit dem Berufsverband Deutscher Dermatologen herausgegeben. Dar\u00fcber hinaus werden auch europ\u00e4ische und internationale dermatologische Leitlinien erstellt, u.\u202fa. durch das im Jahr 2018 vom European Dermatology Forum gegr\u00fcndete European Centre for Guidelines Development. In den Jahren 2019 und 2020 wurden unter anderem deutsche Leitlinien zu den Themen pathologische Narben (hypertrophe Narben und Keloide), kutaner Lupus erythematodes, Pyoderma gangraenosum, analer Pruritus, Analekzem, Analkanal- und Analrandkarzinome, Impfpr\u00e4vention HPV(humane Papillomviren)-assoziierter Neoplasien sowie Syphilis und Systemtherapie bei Neurodermitis \u00fcberarbeitet oder neu erstellt. Auf der europ\u00e4ischen Ebene schlie\u00dft die Leitlinie zum Lichen planus eine in Deutschland noch bestehende L\u00fccke der vorhandenen Leitlinien. Schl\u00fcsselempfehlungen und wesentliche Neuerungen in den Leitlinien werden hier vorgestellt.<\/jats:p>","DOI":"10.1007\/s00105-021-04775-8","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T12:03:16Z","timestamp":1614945796000},"page":"600-606","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aktuelle dermatologische Leitlinien in Deutschland und Europa"],"prefix":"10.1007","volume":"72","author":[{"given":"A.","family":"Nast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. N.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zidane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Heratizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gaskins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"issue":"33","key":"4775_CR1","first-page":"2154","volume":"94","author":"RE Bloch","year":"1997","unstructured":"Bloch\u00a0RE, Lauterbach\u00a0K, Oesingmann\u00a0U et\u00a0al (1997) Bekanntmachungen: Beurteilungskriterien f\u00fcr Leitlinien in der medizinischen Versorgung Beschl\u00fcsse der Vorst\u00e4nde von Bundes\u00e4rztekammer und Kassen\u00e4rztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl Int 94(33):2154\u20132155","journal-title":"Dtsch Arztebl Int"},{"key":"4775_CR2","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2012) AWMF-Regelwerk \u201eLeitlinien\u201c, 1.\u00a0Aufl. http:\/\/www.awmf.org\/leitlinien\/awmf-regelwerk.html. Zugegriffen: 11. Jan. 2016"},{"key":"4775_CR3","volume-title":"European Centre for Guidelines Development (EuroGuiDerm)","author":"A Nast","year":"2020","unstructured":"Nast\u00a0A (2020) European Centre for Guidelines Development (EuroGuiDerm).\u00a0https:\/\/www.edf.one\/de\/home\/Guidelines\/EDF-EuroGuiDerm.html. Zugegriffen: 23. Feb. 2021"},{"key":"4775_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14279","author":"A Nast","year":"2020","unstructured":"Nast\u00a0A, Gauglitz\u00a0G, Lorenz\u00a0K et al (2020) S2k-Leitlinie Therapie pathologischer Narben (hypertrophe Narben und Keloide) \u2013 Update 2020. J\u00a0Dtsch Dermatol Ges. https:\/\/doi.org\/10.1111\/ddg.14279","journal-title":"J Dtsch Dermatol Ges"},{"key":"4775_CR5","series-title":"AWMF-Registernummer 013-060","volume-title":"S2k-Leitlinie \u201eDiagnostik und Therapie des kutanen Lupus erythematodes\u201c","author":"M Worm","year":"2020","unstructured":"Worm\u00a0M (2020) S2k-Leitlinie \u201eDiagnostik und Therapie des kutanen Lupus erythematodes\u201c. AWMF-Registernummer 013-060"},{"key":"4775_CR6","unstructured":"Quist SR et al (2020) S1-Leitlinie Pyoderma gangrenosum (AWMF-Register-Nr.: 013-091). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-091l_S1_Pyoderma-gangrenosum_2020-10_1.pdf. Zugegriffen: 25. Jan. 2021"},{"key":"4775_CR7","unstructured":"Arbeitsgemeinschaft der wissenschaftlichen medizinien Fachgesellschaften (2020) AWMF-S1-Leitlinie \u201eAnaler pruritus\u201c (AWMF-Register Nr.: 013\/063). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-063l_S1_Analer-Pruritis_2020-06.pdf. Zugegriffen: 10. Juli 2020"},{"issue":"8","key":"4775_CR8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/ddg.13304","volume":"15","author":"S Stander","year":"2017","unstructured":"Stander\u00a0S, Zeidler\u00a0C, Augustin\u00a0M et\u00a0al (2017) S2k Guidelines for the diagnosis and treatment of chronic pruritus\u2014update\u2014short version. J\u00a0Dtsch Dermatol Ges 15(8):860\u2013872. https:\/\/doi.org\/10.1111\/ddg.13304","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"4775_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/ddg.14125","volume":"18","author":"G Weyandt","year":"2020","unstructured":"Weyandt\u00a0G, Breitkopf\u00a0C, Werner\u00a0RN et al (2020) S1-Leitlinie \u201eDiagnostik und Therapie des Analekzems\u201c (AWMF-Register Nr.: 013\/007), 2019. J\u00a0Dtsch Dermatol Ges 18(6):648\u2013657. https:\/\/doi.org\/10.1111\/ddg.14125","journal-title":"J Dtsch Dermatol Ges"},{"key":"4775_CR10","unstructured":"Arbeitsgemeinschaft der wissenschaftlichen medizinien Fachgesellschaften (2019) AWMF-S1-Leitlinie \u201eDiagnostik und Therapie des Analekzems\u201c (AWMF-Register Nr.: 013\/007). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-007l_S1_Anakekzem-Diagnostik-Therapie_2019-10_1.pdf. Zugegriffen: 10. Juli 2020"},{"key":"4775_CR11","series-title":"AWMF-Registernummer: 013-027","volume-title":"Aktualisierung \u201eSystemtherapie bei Neurodermitis\u201c zur S2k Leitlinie Neurodermitis","author":"T Werfel","year":"2020","unstructured":"Werfel\u00a0T, Heratizadeh\u00a0A, Abrerer\u00a0W et al (2020) Aktualisierung \u201eSystemtherapie bei Neurodermitis\u201c zur S2k Leitlinie Neurodermitis. AWMF-Registernummer: 013-027"},{"key":"4775_CR12","series-title":"AWMF Registernummer: 081\/004OL","volume-title":"Analkarzinom (Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen), Langversion 1.1","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)","year":"2020","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) Analkarzinom (Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen), Langversion 1.1. AWMF Registernummer: 081\/004OL"},{"key":"4775_CR13","series-title":"AWMF-Register Nr.: 082-002","volume-title":"S3-Leitlinie Impfpr\u00e4vention HPV-assoziierter Neoplasien","author":"GE Gross","year":"2020","unstructured":"Gross\u00a0GE, Wieland\u00a0U, Werner\u00a0RN (2020) S3-Leitlinie Impfpr\u00e4vention HPV-assoziierter Neoplasien. AWMF-Register Nr.: 082-002"},{"key":"4775_CR14","series-title":"AWMF Registernummer: 015\/027OL","volume-title":"Pr\u00e4vention des Zervixkarzinoms, Langversion 1.1","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)","year":"2020","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) Pr\u00e4vention des Zervixkarzinoms, Langversion 1.1. AWMF Registernummer: 015\/027OL"},{"key":"4775_CR15","doi-asserted-by":"publisher","unstructured":"Sch\u00f6fer H, Enders M, Esser S, et\u00a0al. Diagnostik und Therapie der Syphilis : Aktualisierung der S2k-Leitlinie 2020 der Deutsche STI-Gesellschaft (DSTIG) in Kooperation mit folgenden Fachgesellschaften: DAIG, dagn\u00e4, DDG, DGA, DGGG, DGHM, DGI, DGN, DGPI, DGU, RKI. . Hautarzt 2020;71(12):969\u201399. https:\/\/doi.org\/10.1007\/s00105-020-04672-6 [published Online First: 2020\/09\/18]","DOI":"10.1007\/s00105-020-04672-6"},{"key":"4775_CR16","doi-asserted-by":"publisher","unstructured":"Ioannides D, Vakirlis E, Kemeny L, et\u00a0al. European S1 guidelines on the management of lichen planus: a\u00a0cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J\u00a0Eur Acad Dermatol Venereol 2020;34(7):1403\u201314. https:\/\/doi.org\/10.1111\/jdv.16464","DOI":"10.1111\/jdv.16464"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04775-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04775-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04775-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T14:04:26Z","timestamp":1624889066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04775-8"}},"subtitle":["Eine praxisorientierte \u00dcbersicht ausgew\u00e4hlter Empfehlungen"],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4775"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04775-8","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"1 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Nast, R.N.\u00a0Werner, C.\u00a0Dressler, M.\u00a0Zidane, A.\u00a0Heratizadeh\u00a0und M.\u00a0Gaskins geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}